United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

This Recent FDA Approval Is for a Pfizer Vaccine That You'll Probably Never Need

Dell Technologies

Zoom Video

Vaccine updates, the Federal Reserve's annual Jackson Hole symposium, and news out of Afghanistan made for an eventful week on Wall Street.

Benchmarks Log Strong Week Amid News Deluge

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?

Why Is Pfizer (PFE) Up 10.7% Since Last Earnings Report?

Pfizer (PFE) and partner BioNTech ink a collaboration deal with Brazil's Eurofarma for manufacturing and supplying their COVID-19 vaccine, Comirnaty, in Latin America.

Pfizer (PFE) Inks Deal With Eurofarma to Make COVID-19 Vaccine

Direxion Daily Cloud Computing Bull 2X Shares

Direxion Daily Healthcare Bull 3x Shares

MicroSectors Gold Miners 3X Inverse Leveraged ETN

Direxion Daily Technology Bull 3x Shares

ProShares UltraPro QQQ

Amid bouts of volatility and uncertainty, the Wall Street is sizzling this summer buoyed by solid corporate earnings growth and recovering economy.

5 Leveraged/Inverse ETFs Sizzling This Summer

Costco

Medtronic

PepsiCo

Republic Services

Zoetis

Instead of popular but volatile stocks, owning under-the-radar defensive gems will let you sleep at night.

6 Beautifully Boring Dividend Stocks

One ARK Invest exchange-traded fund run by ETF star Cathie Wood bought over 170,000 shares of Pfizer Inc.

Cathie Wood's ARK Invest Buys Over 170,000 Shares of Pfizer

BioNTech SE

Moderna

The teams at Moderna, Pfizer and BioNTech recount the historic race to develop Covid-19 vaccines in a newly released documentary by CNBC.

A race against Covid: How Moderna and Pfizer-BioNTech developed vaccines in record time

AstraZeneca

The risk of developing blood clots is much higher following a Covid-19 infection than after a first dose of either the Pfizer or AstraZeneca vaccine, an Oxford University study has found.

Covid Carries 'Much Higher' Blood Clot Risk Than Pfizer and AstraZeneca Vaccines: Study

Big-time name recognition could lead to big gains for HLS and its investors.

This Pharmaceutical Company Just Got a Major Boost

The government probably prefers to be safe rather than sorry.

Are COVID-19 Boosters Really Needed?

There are several good potential reasons for the move.

Why Is Pfizer Borrowing $1 Billion When Its Cash Stockpile Totals Nearly $22 Billion?

Alibaba

Coinbase

Alphabet

Pinduoduo Inc - ADR

Block

Cathie Wood-led Ark Invest on Thursday piled up yet more shares in the Pinduoduo Inc (NASDAQ:PDD), its third straight buy in the agriculture-focused tech platform after months of trimming its exposure in the Chinese company. The popular money managing firm bought 59,300 shares — estimated to be worth $5.68 million — in Pinduoduo via the Ark Fintech Innovation ETF (NYSE:ARKF).

Pinduoduo, Alibaba, Google, Coinbase, Pfizer, Square — These Are Cathie Wood's Key Trades From Thursday

SPDR Dow Jones Industrial Average ETF

iShares Core S&P 500 ETF

iShares Dow Jones U.S. ETF

JPMorgan Chase & Co

Fidelity NASDAQ Composite Index

Invesco QQQ

SPDR S&P 500 ETF Trust

Vanguard S&P 500 ETF

Wells Fargo

The Wall Street rally is expected to continue on optimism surrounding the vaccine full FDA approval and chances of peaking delta variant cases, which point to recovery from the pandemic-induced slump.

ETFs to Gain on Renewed Market Optimism

For a company that had no cancer drugs two decades ago, Pfizer Inc. ( PFE , Financial) has flipped the switch in a big way. The New York-based pharmaceutical giant's latest effort to beef up its oncology line is its $2.3 billion acquisition of Cambridge, Massachusetts-based biotech Trillium Therapeutics Inc. ( TRIL , Financial).

Pfizer's Covid Technology May Have Cancer Applications

The booster dose of Pfizer (PFE)/BioNTech's (BNTX) mRNA-based COVID-19 vaccine, Comirnaty dose induced significant SARS-CoV-2 neutralizing antibody titers in phase III study.

Pfizer (PFE), BioNTech Seek Full Approval for COVID Jab Booster

Amplify Transformational Data Sharing ETF

iShares Evolved U.S. Technology ETF

iShares North American Tech-Multimedia Networking ETF

iShares U.S. Technology ETF

The 3D Printing ETF

The technology sector has regained strong momentum lately, making it one of the outperforming sectors of this year.

5 Tech ETFs Outperforming the Market This Year

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have partnered with Eurofarma Laboratórios SA, a Brazilian biopharmaceutical company, to manufacture its COVID-19 vaccine for distribution within Latin America. Technical transfer, on-site development, and equipment installation activities will begin immediately.

Pfizer-BioNTech Ink COVID-19 Vaccine Manufacturing Pact For Latin America

The stock price of Pfizer reached an all-time high of $52 last week before a recent sell-off in Covid-19 vaccine stocks drove PFE down to its current level of around $48. PFE stock has fallen 4% over the last five days.

After The Recent 4% Fall Will Pfizer Stock Rebound To Make Fresh Highs?

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that Aamir Malik has joined the company as Executive Vice President and Chief Business Innovation Officer. Mr. Malik will be a member of Pfizer's Executive Leadership Team reporting to Chairman and Chief Executive Officer, Albert Bourla. Mr. Malik joins Pfizer from McKinsey & Company, where he most recently served as the Managing Partner responsible for the firm's U.S. operations. Previously, he led the firm's Global Pharmac

Pfizer Announces New Chief Business Innovation Officer

Pfizer Inc. PFE, -1.80% and BioNTech SE BNTX, +2.13% said Thursday that they have signed a letter of intent (LOI) with Brazil-based biopharmaceutical company Eurofarma Laboratórios SA to make COVID-19 vaccines for distribution in Latin America. Eurofarma will receive drug product from the U.S., and will perform manufacturing activities, with distribution expected to start in 2022.

Pfizer, BioNTech sign LOI with Brazil's Eurofarma to make COVID-19 vaccines for use in Latin America

Johnson & Johnson

Better Healthcare Stock: Johnson & Johnson vs. Pfizer

News for Pfizer Stock (PFE)